Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
Standard
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. / van Lunzen, Jan; Maggiolo, Franco; Arribas, José R; Rakhmanova, Aza; Yeni, Patrick; Young, Benjamin; Rockstroh, Jürgen K; Almond, Steve; Song, Ivy; Brothers, Cindy; Min, Sherene.
in: LANCET INFECT DIS, Jahrgang 12, Nr. 2, 2, 2012, S. 111-118.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
AU - van Lunzen, Jan
AU - Maggiolo, Franco
AU - Arribas, José R
AU - Rakhmanova, Aza
AU - Yeni, Patrick
AU - Young, Benjamin
AU - Rockstroh, Jürgen K
AU - Almond, Steve
AU - Song, Ivy
AU - Brothers, Cindy
AU - Min, Sherene
PY - 2012
Y1 - 2012
N2 - Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses.
AB - Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Viral Load
KW - Dose-Response Relationship, Drug
KW - RNA, Viral/blood
KW - Virus Replication/drug effects
KW - Benzoxazines/administration & dosage
KW - HIV Infections/drug therapy/metabolism/virology
KW - HIV Integrase Inhibitors/administration & dosage
KW - HIV-1/physiology
KW - Heterocyclic Compounds, 3-Ring/administration & dosage
KW - Reverse Transcriptase Inhibitors/administration & dosage
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Viral Load
KW - Dose-Response Relationship, Drug
KW - RNA, Viral/blood
KW - Virus Replication/drug effects
KW - Benzoxazines/administration & dosage
KW - HIV Infections/drug therapy/metabolism/virology
KW - HIV Integrase Inhibitors/administration & dosage
KW - HIV-1/physiology
KW - Heterocyclic Compounds, 3-Ring/administration & dosage
KW - Reverse Transcriptase Inhibitors/administration & dosage
M3 - SCORING: Journal article
VL - 12
SP - 111
EP - 118
JO - LANCET INFECT DIS
JF - LANCET INFECT DIS
SN - 1473-3099
IS - 2
M1 - 2
ER -